{
  "docId": "019de076-213d-70dd-a534-653b847b5e3f",
  "docSlug": "a748211b037be53bd983a1c4e3bfc311",
  "documentTitle": "argenx SE | Investor Presentation Deck | 7 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 7,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a timeline-based clinical trial design framework.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-213d-70dd-a534-653b847b5e3f/4",
  "deckHref": "/decks/019de076-213d-70dd-a534-653b847b5e3f",
  "deckJsonHref": "/decks/019de076-213d-70dd-a534-653b847b5e3f.json",
  "deckAnchorHref": "/decks/019de076-213d-70dd-a534-653b847b5e3f#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.25,
        "y": 0.34
      },
      "kind": "diagram",
      "text": "Patients randomized 2:1 to receive VYVGART Hytrulo or placebo (24 weeks)",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d145edc6-4977-4d4d-8b4b-40f5a336e5ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.22,
        "x": 0.04,
        "y": 0.215
      },
      "kind": "list",
      "text": "Adult Chronic or Persistent ITP patients\n2 weeks screening\nMean platelet count <30x10^9/L\nStable concomitant ITP therapy allowed\nStratification: splenectomy, concomitant ITP therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "064b43fc-b927-4666-b328-3f25cf62243f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.76
      },
      "kind": "paragraph",
      "text": "207 patients enrolled\nPatients were heavily pre-treated and 75% of patients had received three or more prior ITP therapies",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7d97379-1e3a-40ac-9554-fa09d7eb405d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.17,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "Primary endpoint: Sustained platelet count (≥50x10^9/L) in ≥4/6 visits between weeks 19 and 24",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebd6551f-c42a-4bd1-928a-4668ce194e6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.28,
        "x": 0.036,
        "y": 0.06
      },
      "kind": "title",
      "text": "ITP ADVANCE-SC Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "009cf25a-5db0-46a4-b79b-5b2eac62c8ec",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "91d09b6d-be44-4684-8e30-dbe42e1f6da2",
      "evidence": "The slide presents information in a list format.",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "88380379-90e8-400c-a929-a3bc2bb4da9e",
      "evidence": "Timeline and patient criteria for a clinical study",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 4,
      "from": 4,
      "beatId": "47e73aa4-2e1d-444d-86e8-cc1c294f1576",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "ITP ADVANCE-SC Trial",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "87b7f924-5d07-4995-9c4d-f983349403a3",
      "evidence": "emphasis on transforming severe autoimmunity",
      "position": 0,
      "objective": "Highlighting the need for innovative treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}